Valeant (VRX) PT Cut to $33 at RBC Capital
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/19/2026
- Wall St rises as yields ease, Moderna lifts healthcare stocks
- U.S. Treasury doubles buyback operation size for long-dated bonds
- Marvell shares jump after giving Google warrants amid custom chip deal
- U.S. debt tops $40 trillion
- Nvidia credit risk gauge hits new peak as SoftBank readies record bond issue
- Marvell issues Google warrant tied to custom chip deal
- Tech selloff weighs down Wall Street as bond yields climb
- FOMC minutes from July 28-29th meeting
- Lowe's Cos. (LOW) Tops Q2 EPS by 17c, Misses on Revenue; Offers Fy27 Guidance
- Nvidia or Sandisk? BofA reveals which stock is under-owned and which is crowded
Valeant Pharmaceuticals Reports First Quarter 2016 Financial Results
June 7, 2016 6:00 AM EDTLAVAL, Quebec, June 7, 2016 /PRNewswire/ --
Total Revenues of $2.4 billion, an increase of 9% versus the first quarter of 2015 (restated) GAAP EPS ($1.08); Adjusted EPS (non-GAAP) $1.27 GAAP Cash Flow from Operations was $558 million, an increase of 14% versus the first quarter of 2015 (restated) Updated Full Year 2016 Guidance: Total Revenue updated to $9.9 - $10.1 billion from $11.0 - $11.2 billion Adjusted EPS (non-GAAP) updated to $6.60 - $7.00 from $8.50 - $9.50 Adjusted EBITDA (non-GAAP) is updated to $4.80 - $4.95 billion from $5.60 - $5.80 billionValeant Pharmaceuticals International,... More
